Compare Domino's Pizza, Inc. (DPZ) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs GSK plc — how do they compare? Domino's Pizza, Inc. trades at $309.23 (market cap $10.21B), while GSK plc trades at $46.52 (market cap $91.88B). The key difference: GSK plc is far larger — about 9× Domino's Pizza, Inc.'s market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Domino's Pizza, Inc. for 106 Days and GSK plc for 93 Days on average.
| DPZ | GSK | |
|---|---|---|
Market Cap | $10.21B | $91.88B |
Volume | 916,737 | 7,730,529 |
Sector | Consumer Cyclical | Health |
52-Week High | $438.42 | $61.18 |
52-Week Low | $282.89 | $43.24 |
Typical Hold Time | 106 Days | 93 Days |
Enterprise Value | $15.17B | $111.88B |
Dividend Yield | 2.58% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $309.02, up 1.95% with a bullish technical signal despite recent earnings misses. The company maintains strong fundamentals with $4.94B revenue, 11.86% net margin, and positive cash flow trends. Recent news highlights dividend stability concerns amid high debt levels and store closures, while analyst consensus remains positive with a $373 price target representing 21% upside potential.
DPZ presents a value opportunity with reasonable valuation (P/E 17.5) but faces execution risks from consecutive earnings misses and substantial debt burden. The stock's 28% YTD decline creates potential for recovery if Q3 earnings beat expectations, though competitive pressures and franchisee challenges require monitoring for sustained growth.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
